Immunic Presents Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS Meeting

NEW YORK - Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced that...

Related Keywords

Cleveland ,Ohio ,United States ,Russia ,Milan ,Lombardia ,Italy ,Ukraine ,Robertj Fox ,Daniel Vitt ,Jessica Breu ,Mellen Center ,Nasdaq ,Neurological Institute ,Immunic Inc ,Exchange Commission ,Staff Neurologist ,Multiple Sclerosis ,Coordinating Investigator ,Chief Executive Officer ,Neurofilament Light Chain ,Vidofludimus Calcium ,Poster Number ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,News Publishing ,Markets ,